Scott Chappel, PhD

Scott Chappel, PhDAt Surface, Scott oversees all antibody generation, engineering, production and protein characterization. He also oversees all preclinical IND enabling studies and GMP manufacturing of antibodies. Scott is an accomplished scientist who has directed research that led to the development of several FDA-approved and marketed biological products. Scott joins Surface from Arteaus Therapeutics (acquired by Eli Lilly in 2014) where he was co-founder and Chief Scientific Officer. Prior to Arteaus, Scott was a Founder and Chief Scientific Officer of Tokai Pharmaceuticals, where he worked to develop oral therapeutic for prostate cancer. Prior to Tokai, he was Senior Vice President of Research at Dyax, identifying therapeutic antibodies using phage display. Prior to Dyax he was Chief Scientist at Serono. Scott received his PhD in neuroscience from the University of Maryland School of Medicine. He has authored or co-authored more than 65 peer-reviewed scientific publications and been named inventor on 19 issued U.S. patents.